Clinical Pharmacokinetics of the Androgen Receptor Inhibitor Darolutamide in Healthy Subjects and Patients with Hepatic or Renal Impairment

por Zurth, Christian, Nykänen, Pirjo, Wilkinson, Gary, Taavitsainen, Päivi, Vuorela, Annamari, Huang, Funan, Reschke, Susanne, Koskinen, Mikko
Publicado 2021

Drug–Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies

por Zurth, Christian, Koskinen, Mikko, Fricke, Robert, Prien, Olaf, Korjamo, Timo, Graudenz, Kristina, Denner, Karsten, Bairlein, Michaela, von Bühler, Clemens-Jeremias, Wilkinson, Gary, Gieschen, Hille
Publicado 2019

Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer—Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Ef...

por Schneeweiss, Andreas, Hess, Dagmar, Joerger, Markus, Varga, Andrea, Moulder, Stacy, Tsimberidou, Apostolia M., Ma, Cynthia, Hurvitz, Sara A., Rentzsch, Christine, Rudolph, Marion, Thiele, Silke, Boix, Oliver, Wilkinson, Gary, Lagkadinou, Eleni, Ocker, Matthias
Publicado 2019

Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results

por Heuser, Michael, Palmisiano, Neil, Mantzaris, Ioannis, Mims, Alice, DiNardo, Courtney, Silverman, Lewis R., Wang, Eunice S., Fiedler, Walter, Baldus, Claudia, Schwind, Sebastian, Pardee, Timothy, Perl, Alexander E., Cai, Charles, Kaulfuss, Stefan, Lagkadinou, Eleni, Rentzsch, Christine, Wagner, Markus, Wilkinson, Gary, Wu, Bingyan, Jeffers, Michael, Genvresse, Isabelle, Krämer, Alwin
Publicado 2020